QBW 276Alternative Names: QBW276
Latest Information Update: 22 Mar 2016
At a glance
- Originator Novartis
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 10 Mar 2016 Novartis withdraws a phase I/II trial for Cystic fibrosis in USA, United Kingdom and Germany (NCT02566044)
- 18 Sep 2015 Novartis plans a phase I/II trial for Cystic fibrosis in USA, United Kingdom and Germany (NCT02566044)